Quanterix (QTRX)
Builds Simoa and spatial biology tools for ultra-sensitive biomarker research and diagnostics.
Something off on this page? Send us feedback.
Sells instruments, assay kits, consumables, lab services, and diagnostics-facing tests built around Simoa protein detection and Akoya spatial biology. Revenue is reported in one segment, while operations are centered in Massachusetts with most employees in the United States and a smaller international base.
Built around Simoa, the platform detects low-abundance protein biomarkers in blood, serum, and other fluids through instruments, assay kits, consumables, custom assay work, and the Simoa Accelerator Laboratory.
After the Akoya acquisition, the scope includes spatial biology instruments, reagents, software, and services for tissue analysis and spatial phenotyping. The portfolio now spans blood and tissue, with diagnostic-facing activity through Lucent Diagnostics and Alzheimer's blood-test development.
Headquartered in Billerica, Massachusetts, the employee base is concentrated in the United States with a smaller presence across foreign countries. The business depends on instrument, consumables, services, and assay adoption by research, biopharmaceutical, diagnostics, and clinical customers, plus Akoya integration and diagnostic regulatory and reimbursement execution.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $4 | Target: $3 |
| Apr 20, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $8 | Target: $4 |
| Dec 22, 2025 | Canaccord Genuity | Reiterate | Rating: —Target: $25 | Target: $8 |
| Aug 11, 2025 | Canaccord Genuity | Downgrade | ||
| Apr 30, 2025 | Leerink Partners | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $93.5M · Total debt $33.4M · Total assets $319.6M · Shareholders' equity $237.2M
- Revenue
- $32.9M
- Operating income
- −$49.4M
- Net income
- −$48.9M
No dividends on record.
| Institutions | ≈ 62.87% | 29.73M shares | |
|---|---|---|---|
| 136 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.27% | 1.55M shares | |
| 15 holders · as of Sep 16, 2026 | |||
| Strategic holders | 6.67% | 3.15M shares | |
| 1 holder · as of Feb 11, 2022 | |||
| Other | ≈ 27.19% | 12.86M shares | |
| remainder | |||
47.29M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.69% | 3.64M | as of Jun 30, 2026 |
Blue Water Life Science Advisors, LPInstitution | 7.35% | 3.47M | as of Jun 30, 2026 |
Macquarie Group LimitedStrategic | 6.67% | 3.15M | filed Feb 11, 2022 |
LLCInstitution | 6.00% | 2.84M | filed Feb 14, 2022 |
First Eagle Investment Management, LLCInstitution | 5.82% | 2.75M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | William P. Donnelly | director | +72,245 | $2.93 |
| Aug 12, 2026 | William P. Donnelly | director | +27,155 | $2.75 |
| May 12, 2026 | Benjamin Meadows | officer: Chief Commercial Officer | +3,500 | $2.77 |
- Bio-Techne
Automated immunoassay and spatial biology workflows
- Bruker
Spatial biology platforms and multiomic services
- 10x Genomics
Single-cell and spatial genomics for tissue analysis
- Bio-Rad Laboratories
Multiplex immunoassays and clinical diagnostics scale
- Quest Diagnostics
Alzheimer's blood testing and national lab access
- Standard BioTools
Spatial proteomics tools and lab services
- Seer
Deep plasma proteomics for discovery studies
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quanterix | $3.08 | −3.52% | $150.3M | — | — | 1.0 | +34.4% |
| Bio-Techne | $72.54 | −0.01% | $11.36B | 62.5 | 35.0 | 9.3 | +1.3% |
| Bruker | $61.25 | +0.06% | $9.32B | — | 27.0 | 2.7 | +5.2% |
| 10x Genomics | $77.65 | −3.78% | $10.25B | — | — | 16.6 | −12.7% |
| Bio-Rad Laboratories | $377.47 | −0.55% | $10.22B | 46.0 | 36.6 | 3.9 | −0.1% |
| Quest Diagnostics | $237.42 | +1.13% | $25.92B | 24.9 | 20.7 | 2.2 | +10.2% |
| Standard BioTools | $0.7314 | −2.45% | $293.5M | — | — | 3.5 | −7.6% |
| Seer | $1.82 | −2.15% | $102.3M | — | — | 7.4 | −23.4% |
| Median | 46.0 | 31.0 | 3.9 | −0.1% |